Buy Acadia
Amount
Latest price
$22.57
(£1.00 = $1.316)
Number of shares (est.)
0
Start investing today
Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.
Metrics
Market Cap
$3.653B
P/E ratio
13.90
EPS
$1.558
Beta
0.69
Dividend rate
N/A
Dividend yield
N/A
About
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
CEO
Ms. Catherine Owen Adams
Employees
653
Sector
Health
Company HQ
SAN DIEGO, United States of America
Website
News
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. ( ACAD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Albert Kildani Catherine Owen Adams - CEO & Director Thomas Garner - Executive VP & Chief Commercial Officer Elizabeth Thompson - Executive VP and Head of Research & Development Mark Schneyer - Executive VP & CFO Conference Call Participants Ritu Baral - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division So Youn Shim - UBS Investment Bank, Research Division Samuel Beck - Deutsche Bank AG, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Sean Laaman - Morgan Stanley, Research Division Tazeen Ahmad - BofA Securities, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Julian Hung - Stifel Nicolaus Canada Inc., Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Poorna Kannan - Needham & Company, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good day, ladies and gentlemen, and thank you for standing by.
Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe, Emma vs Moneyhub.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.